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Y
ou can learn a lot if you have 
the right tool to help your inves-
tigations along. But where those 
tools don’t exist, you may have to work 
on a different question. Ulrike Eggert 
isn’t about to let a little thing like the 
lack of a tool get in her way—she’ll just 
make her own.
Since her postdoc in Tim Mitchison’s 
lab at Harvard (1), Eggert has used a com-
bination of RNAi and small molecules in 
phenotypic screens to identify new ways 
to interrogate biological pathways (1, 2). 
She’s chosen to focus on cytokinesis, a 
biological process that happens so quickly 
it’s been diffi  cult to study by other means 
(3–5). We called her at her new lab at 
King’s College, London, to discuss the 
advantages she’s enjoyed and the hurdles 
she’s surmounted in her efforts to add to 
the scientifi  c toolbox.
NEW FIELDS
You came to biology from a chemistry 
background?
My undergraduate and graduate degrees 
are in chemistry. I did my PhD in Daniel 
Kahne’s lab, who was then in the chemis-
try department at Princeton. 
He was interested in apply-
ing ideas from chemistry to 
biological research and was 
just getting started on that. I 
think that’s what attracted 
me to his lab, apart from the 
fact that he’s a really great 
mentor. Another student had 
found that if you attach a 
glycolipid moiety to the anti-
biotic vancomycin, it be-
comes active against vancomycin-resistant 
bacteria. My project was to study how that 
happens. For both of us, it was a journey 
into biology.
I think that’s really when my interest 
in what’s now a big part of my research 
started. That’s also why I chose to do a 
postdoc with Tim Mitchison, because 
he was one of the pioneers in the fi  eld of 
using small molecules to probe biology. 
Since I’m a chemist and I have never 
taken a biology class, I thought it would 
be good for me to learn biology in a 
hardcore biology lab that still had an 
understanding of chemistry.
In Tim’s lab I collaborated with a post-
doc in Norbert Perrimon’s lab, Amy Kiger, 
to do one of the fi  rst visual full-genome 
RNAi screens in Drosophila. It was a good 
opportunity because I also did a small mol-
ecule screen in parallel, and it gave me a 
chance to combine the two approaches. 
This got me thinking about how small 
molecules and RNAi are in some ways 
complementary and how one can take 
advantage of both the similarities and dif-
ferences between them.
What are some of the advantages and 
drawbacks of using small molecules to 
probe pathways?
The biggest advantage of small molecules 
is that they act very quickly, so they can 
be used to study dynamic systems. Also, 
their action is often—but not always—
reversible, so you can add a small mole-
cule and then wash it out and observe the 
effects. The main disadvantage of small 
molecules is that we do not 
have a small molecule that 
binds to every protein that 
we’re interested in, and the 
process of getting them is 
very difficult. That’s in 
contrast to RNAi, which 
you can use to knock down 
pretty much any protein 
you want to, as long as you 
know the sequence of its 
mRNA. But I think the dis-
advantage of RNAi is that, because 
you’re depleting a protein by destroying 
its mRNA, it takes time to completely 
take effect, and cells can sometimes 
adapt to gradually decreasing amounts of 
a given protein.
Sometimes the phenotypes caused by 
small molecules and RNAi can be differ-
ent because with RNAi the protein is gone 
but with small molecules the protein is 
still there and you’re inhibiting maybe 
just one function of the protein. So, often 
the phenotypes of small molecules and 
RNAi are the same, but sometimes they 
aren’t, and I think that’s interesting.
NEW TOOLS
How do you go about developing a new 
small molecule tool?
There are two ways in which one can fi  nd 
a small molecule tool: a protein-based 
screen or a phenotypic screen. The pro-
tein-based screen is basically what most 
of the pharmaceutical industry does, 
where you purify a protein for which you 
have some kind of functional assay, then 
do a screen to fi  nd small molecules that 
inhibit that protein. It’s possible to screen 
hundreds of thousands of compounds using 
a plate reader, but the main limitations 
are that one can only target proteins with 
detectable activities and that you don’t 
know how specifi  c your small molecule 
will be for its desired activity.
Some basic researchers instead use a 
phenotypic screen, where you add a 
small molecule to cells and you look for 
a phenotype that suggests your com-
pound inhibits your pathway of interest. 
This is often done using a high-throughput 
microscope, and you can take pictures of 
treated cells in multi-well plates. In that 
approach you know you’re getting a specifi  c 
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Eggert uses RNAi and chemistry to develop novel tools for investigating cytokinesis.
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“The biggest 
advantage 
of small 
molecules is 
that they 
act very 
quickly.”
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small molecule because you’re looking 
for a specifi  c phenotype. But the huge, 
huge challenge—and the reason why the 
pharmaceutical industry doesn’t use this 
approach as much—is that it’s diffi  cult to 
fi  nd the target of the small molecule that 
gives rise to the phenotype that you’re 
interested in.
What approaches can be used to identify 
a small molecule’s target?
One approach is the one I initiated during 
my postdoc, which was to compare the 
phenotypes between small molecules and 
RNAi. The idea was that if a small mole-
cule and RNAi phenotype are the same, 
then in many cases they would target the 
same protein (although there are the cave-
ats that I mentioned earlier). 
We used this approach to 
identify small molecules that 
target proteins involved in 
cytokinesis, which is a very 
fast process that is diffi  cult 
to study using RNAi or other 
genetic methods because 
many of the proteins that 
are involved in cytokinesis 
are also involved in the step 
before, mitosis.
When I started my lab at 
the Dana-Farber Cancer In-
stitute and Harvard Medical 
School, we began working 
on another approach: combining RNAi 
and small molecules in a different way to 
identify the small molecules’ targets. We 
wanted to fi  nd small molecules that target 
Rho signaling during cytokinesis. The 
Rho GTPase pathway is really important 
in regulating many aspects of the cyto-
skeleton, but there are not many small 
molecules available to study proteins in 
that pathway. It would be nice if we could 
target Rho directly, but people haven’t 
found any small molecules that target 
small GTPases because GTP binds very 
tightly to them and it’s diffi  cult to inter-
fere with that interaction. We can’t com-
pete with huge pharma companies that 
have tried for decades to fi  nd small mole-
cules that bind to GTPases specifi  cally, so 
we thought we’d look at the actual path-
way itself. The way we did that is that we 
sensitized cells by doing partial RNAi of 
Rho GTPase, and then we looked for 
small molecules that either increased the 
RNAi phenotype or suppressed it. And by 
doing that, we found a number of small 
molecules that we know target Rho sig-
naling in cytokinesis. We 
don’t know yet precisely 
which proteins in the Rho 
pathway most of the com-
pounds bind to, but that’s 
one thing my lab is working 
on right now.
NEW DIRECTIONS
What else are you working 
on right now?
I’m currently moving my 
lab to King’s College, Lon-
don, but I have two post-
docs who will be staying 
at my lab at Harvard, and 
they’re both working on aspects that are 
connected to membrane traffi  cking and 
the role of the membrane in cytokinesis. 
One is working on a small molecule we 
discovered that’s a very potent inhibitor 
of cytokinesis and that also induces endo-
cytic tubules. These are novel structures 
that stain positive for a number of dif-
ferent endocytic markers and al-
most look cytoskeletal but that don’t 
associate with any cytoskeletal fea-
tures that we’ve looked at. It’s got 
us looking at connections between 
endocytosis and cytokinesis.
The other postdoc is looking at 
the nature of the lipids involved in 
cytokinesis, using lipodomics and 
lipid profi  ling, asking questions such 
as whether there are changes in the 
lipid composition of dividing cells versus 
interphase cells. In a warm-up experi-
ment for that, we used different small 
molecules to inhibit different lipid bio-
synthetic pathways, and we found that, 
if you inhibit ceramide biosynthesis, 
then you also inhibit cytokinesis.
Is your approach to your work different 
than that of your biologist colleagues’?
Chemistry as a fi  eld is much more inter-
ested in discovery-driven research, where-
as in biology there’s more emphasis on 
hypothesis-driven research. Discovery-
driven research involves screening or doing 
experiments where you can’t predict what 
the outcome will be or where you can’t 
hypothesize what the outcome will be. I 
think, in general, the more traditional biolo-
gist prefers experiments where people 
say, “I think that protein X does this, and 
I will test it in the following ways.” That’s 
a valuable approach, but I think using a 
less hypothesis-driven approach to gener-
ate new tools that can then provide new 
insights is also valuable.
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Early endosomes (yellow) and recycling 
endosomes (red) accumulate at the cleavage 
furrow in a dividing HeLa cell.
“Discovery-
driven 
research 
involves… 
experiments 
where you 
can’t predict 
what the 
outcome 
will be.”
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Eggert, with members of her Harvard and King’s 
College labs.